Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain

Nathaniel Katz, Martin Hale, David Morris, Joseph Stauffer

Research output: Contribution to journalArticle

Abstract

Objective: To assess the efficacy and safety of morphine sulfate and naltrexone hydrochloride extended release capsules (EMBEDA®; MS-sNT), which contain morphine sulfate pellets with a sequestered naltrexone core, in treating patients with chronic, moderate-to-severe osteoarthritis (hip or knee) pain. Patients and Methods: This phase 3 study had an enriched-enrollment, randomized-withdrawal, double-blind, multicenter design. Patients (N = 547) were titrated to an effective dose of MS-sNT (20-160 mg/day). Responders (n = 344) were randomized to 12 weeks maintenance with an effective MS-sNT dose or were tapered to placebo over 2 weeks. The primary efficacy measure was the change from baseline (CFB) in diary average-pain scores (0-10 scale, Brief Pain Inventory [BPI]) from randomization to the last 7 days of the maintenance period. Secondary efficacy measures included the remaining BPI scores and Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index. Opioid withdrawal symptoms were assessed by the Clinical Opiate Withdrawal Scale (COWS) and Subjective Opiate Withdrawal Scale (SOWS). The study ran from January 10, 2007 through November 8, 2007. Results: MS-sNT maintained pain control better than placebo (mean CFB, diary average-pain score, -0.2 ± 1.9 vs +0.3 ± 2.1; P = 0.045). Change from baseline for MS-sNT pain-diary score (worst, least, average, current) was superior during the maintenance period visits, weeks 2 to 12 (P <0.05). WOMAC composite score CFB was superior at most visits. MS-sNT was generally well tolerated, with a typical morphine safety profile. No patient taking MS-sNT as directed experienced withdrawal symptoms. Conclusion: MS-sNT provided effective analgesia in patients with chronic, moderate-to-severe osteoarthritis pain, with a safety profile typical of morphine-containing products. Naltrexone sequestered in MS-sNT had no clinically relevant effect when MS-sNT was taken as directed.

Original languageEnglish (US)
Pages (from-to)112-128
Number of pages17
JournalPostgraduate Medicine
Volume122
Issue number4
DOIs
StatePublished - Jul 2010

Fingerprint

Naltrexone
Chronic Pain
Osteoarthritis
Morphine
Capsules
Pain
Opiate Alkaloids
Substance Withdrawal Syndrome
Maintenance
Safety
Placebos
Equipment and Supplies
Hip Osteoarthritis
Knee Osteoarthritis
Ontario
Random Allocation
Analgesia
Opioid Analgesics

Keywords

  • Chronic pain
  • Extended release
  • Morphine
  • Opioid withdrawal
  • Opioids

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain. / Katz, Nathaniel; Hale, Martin; Morris, David; Stauffer, Joseph.

In: Postgraduate Medicine, Vol. 122, No. 4, 07.2010, p. 112-128.

Research output: Contribution to journalArticle

Katz, Nathaniel ; Hale, Martin ; Morris, David ; Stauffer, Joseph. / Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain. In: Postgraduate Medicine. 2010 ; Vol. 122, No. 4. pp. 112-128.
@article{d1c48e0c09084ce59424d60f5650a65a,
title = "Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain",
abstract = "Objective: To assess the efficacy and safety of morphine sulfate and naltrexone hydrochloride extended release capsules (EMBEDA{\circledR}; MS-sNT), which contain morphine sulfate pellets with a sequestered naltrexone core, in treating patients with chronic, moderate-to-severe osteoarthritis (hip or knee) pain. Patients and Methods: This phase 3 study had an enriched-enrollment, randomized-withdrawal, double-blind, multicenter design. Patients (N = 547) were titrated to an effective dose of MS-sNT (20-160 mg/day). Responders (n = 344) were randomized to 12 weeks maintenance with an effective MS-sNT dose or were tapered to placebo over 2 weeks. The primary efficacy measure was the change from baseline (CFB) in diary average-pain scores (0-10 scale, Brief Pain Inventory [BPI]) from randomization to the last 7 days of the maintenance period. Secondary efficacy measures included the remaining BPI scores and Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index. Opioid withdrawal symptoms were assessed by the Clinical Opiate Withdrawal Scale (COWS) and Subjective Opiate Withdrawal Scale (SOWS). The study ran from January 10, 2007 through November 8, 2007. Results: MS-sNT maintained pain control better than placebo (mean CFB, diary average-pain score, -0.2 ± 1.9 vs +0.3 ± 2.1; P = 0.045). Change from baseline for MS-sNT pain-diary score (worst, least, average, current) was superior during the maintenance period visits, weeks 2 to 12 (P <0.05). WOMAC composite score CFB was superior at most visits. MS-sNT was generally well tolerated, with a typical morphine safety profile. No patient taking MS-sNT as directed experienced withdrawal symptoms. Conclusion: MS-sNT provided effective analgesia in patients with chronic, moderate-to-severe osteoarthritis pain, with a safety profile typical of morphine-containing products. Naltrexone sequestered in MS-sNT had no clinically relevant effect when MS-sNT was taken as directed.",
keywords = "Chronic pain, Extended release, Morphine, Opioid withdrawal, Opioids",
author = "Nathaniel Katz and Martin Hale and David Morris and Joseph Stauffer",
year = "2010",
month = "7",
doi = "10.3810/pgm.2010.07.2179",
language = "English (US)",
volume = "122",
pages = "112--128",
journal = "Postgraduate Medicine",
issn = "0032-5481",
publisher = "Medquest Communications LLC",
number = "4",

}

TY - JOUR

T1 - Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain

AU - Katz, Nathaniel

AU - Hale, Martin

AU - Morris, David

AU - Stauffer, Joseph

PY - 2010/7

Y1 - 2010/7

N2 - Objective: To assess the efficacy and safety of morphine sulfate and naltrexone hydrochloride extended release capsules (EMBEDA®; MS-sNT), which contain morphine sulfate pellets with a sequestered naltrexone core, in treating patients with chronic, moderate-to-severe osteoarthritis (hip or knee) pain. Patients and Methods: This phase 3 study had an enriched-enrollment, randomized-withdrawal, double-blind, multicenter design. Patients (N = 547) were titrated to an effective dose of MS-sNT (20-160 mg/day). Responders (n = 344) were randomized to 12 weeks maintenance with an effective MS-sNT dose or were tapered to placebo over 2 weeks. The primary efficacy measure was the change from baseline (CFB) in diary average-pain scores (0-10 scale, Brief Pain Inventory [BPI]) from randomization to the last 7 days of the maintenance period. Secondary efficacy measures included the remaining BPI scores and Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index. Opioid withdrawal symptoms were assessed by the Clinical Opiate Withdrawal Scale (COWS) and Subjective Opiate Withdrawal Scale (SOWS). The study ran from January 10, 2007 through November 8, 2007. Results: MS-sNT maintained pain control better than placebo (mean CFB, diary average-pain score, -0.2 ± 1.9 vs +0.3 ± 2.1; P = 0.045). Change from baseline for MS-sNT pain-diary score (worst, least, average, current) was superior during the maintenance period visits, weeks 2 to 12 (P <0.05). WOMAC composite score CFB was superior at most visits. MS-sNT was generally well tolerated, with a typical morphine safety profile. No patient taking MS-sNT as directed experienced withdrawal symptoms. Conclusion: MS-sNT provided effective analgesia in patients with chronic, moderate-to-severe osteoarthritis pain, with a safety profile typical of morphine-containing products. Naltrexone sequestered in MS-sNT had no clinically relevant effect when MS-sNT was taken as directed.

AB - Objective: To assess the efficacy and safety of morphine sulfate and naltrexone hydrochloride extended release capsules (EMBEDA®; MS-sNT), which contain morphine sulfate pellets with a sequestered naltrexone core, in treating patients with chronic, moderate-to-severe osteoarthritis (hip or knee) pain. Patients and Methods: This phase 3 study had an enriched-enrollment, randomized-withdrawal, double-blind, multicenter design. Patients (N = 547) were titrated to an effective dose of MS-sNT (20-160 mg/day). Responders (n = 344) were randomized to 12 weeks maintenance with an effective MS-sNT dose or were tapered to placebo over 2 weeks. The primary efficacy measure was the change from baseline (CFB) in diary average-pain scores (0-10 scale, Brief Pain Inventory [BPI]) from randomization to the last 7 days of the maintenance period. Secondary efficacy measures included the remaining BPI scores and Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index. Opioid withdrawal symptoms were assessed by the Clinical Opiate Withdrawal Scale (COWS) and Subjective Opiate Withdrawal Scale (SOWS). The study ran from January 10, 2007 through November 8, 2007. Results: MS-sNT maintained pain control better than placebo (mean CFB, diary average-pain score, -0.2 ± 1.9 vs +0.3 ± 2.1; P = 0.045). Change from baseline for MS-sNT pain-diary score (worst, least, average, current) was superior during the maintenance period visits, weeks 2 to 12 (P <0.05). WOMAC composite score CFB was superior at most visits. MS-sNT was generally well tolerated, with a typical morphine safety profile. No patient taking MS-sNT as directed experienced withdrawal symptoms. Conclusion: MS-sNT provided effective analgesia in patients with chronic, moderate-to-severe osteoarthritis pain, with a safety profile typical of morphine-containing products. Naltrexone sequestered in MS-sNT had no clinically relevant effect when MS-sNT was taken as directed.

KW - Chronic pain

KW - Extended release

KW - Morphine

KW - Opioid withdrawal

KW - Opioids

UR - http://www.scopus.com/inward/record.url?scp=77956640307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956640307&partnerID=8YFLogxK

U2 - 10.3810/pgm.2010.07.2179

DO - 10.3810/pgm.2010.07.2179

M3 - Article

C2 - 20675975

AN - SCOPUS:77956640307

VL - 122

SP - 112

EP - 128

JO - Postgraduate Medicine

JF - Postgraduate Medicine

SN - 0032-5481

IS - 4

ER -